...
首页> 外文期刊>International Journal of Pharmaceutics >Propranolol-magnesium aluminum silicate complex dispersions and particles:Characterization and factors influencing drug release
【24h】

Propranolol-magnesium aluminum silicate complex dispersions and particles:Characterization and factors influencing drug release

机译:普萘洛尔-镁铝硅酸盐复合物分散体和颗粒:表征及影响药物释放的因素

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, complexation of magnesium aluminum silicate (MAS) and propranolol HC1 (PPN) in the form of dispersions and solid particles was investigated. PPN-MAS dispersions at different pHs were prepared and characterized. The physicochemical properties and in vitro drug release of the complexes were also examined. Incorporation of PPN into MAS dispersions at various pHs caused the formation of PPN-MAS flocculates with a different particle size, zeta potential and amount of PPN adsorbed. The PPN-MAS complexes prepared at various pHs were formed via cation exchange, hydrogen bonding and water bridging mechanisms, which were revealed by FTIR and solid-state ~29Si NMR spectroscopy. This led to the intercalation of PPN molecules into the silicate layers of MAS. In vitro drug release studies demonstrated that the kinetic release of PPN can be described using the particle diffusion controlled mechanism, suggesting that drug release was controlled by diffusion of the drug in aqueous channels in the particle matrix of the complexes. The PPN-MAS complexes provided a sustained-release of PPN after an initial burst release in acidic medium and pH 6.8 phosphate buffer when compared with the physical mixture and pure PPN powder. This was due to a slow diffusion of drug that was intercalated in the inside of the particle matrix. The preparation pH of the complexes did not influence the release of PPN; the important factors affecting drug release were particle size, percentage of drug loaded in the complexes and the type of release medium. This finding suggests that the PPN-MAS complexes obtained in this study are strong candidates for use as drug carriers in oral modified-release dosage forms.
机译:在这项研究中,研究了分散体和固体颗粒形式的硅酸铝镁(MAS)和普萘洛尔HCl(PPN)的络合。制备并表征了在不同pH值下的PPN-MAS分散体。还检查了复合物的理化性质和体外药物释放。在不同pH值下将PPN掺入MAS分散液中会导致形成PPN-MAS絮凝物,而该絮凝物具有不同的粒径,ζ电势和吸附的PPN量。通过阳离子交换,氢键和水桥联机制形成了在各种pH值下制备的PPN-MAS络合物,这通过FTIR和固态〜29Si NMR光谱法得以揭示。这导致PPN分子插入到MAS的硅酸盐层中。体外药物释放研究表明,可以使用颗粒扩散控制机制来描述PPN的动力学释放,这表明药物释放是通过药物在复合物颗粒基质中水通道中的扩散来控制的。与物理混合物和纯PPN粉末相比,PPN-MAS复合物在酸性介质和pH 6.8磷酸盐缓冲液中初次释放后提供了PPN的持续释放。这是由于插在颗粒基质内部的药物缓慢扩散所致。配合物的制备pH值不影响PPN的释放。影响药物释放的重要因素是粒径,复合物中载药的百分比和释放介质的类型。这一发现表明,在这项研究中获得的PPN-MAS复合物是用作口服调释剂型中药物载体的强大候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号